title: Tat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and Meta-Analysis.
abstract: BACKGROUND
  Tat-interacting protein 30 (TIP30) is a tumor suppressor protein that has been found to be expressed in a wide variety of tumor tissues. TIP30 is involved in the control of cell apoptosis, growth, metastasis, angiogenesis, DNA repair, and tumor cell metabolism. The methylation of the TIP30 promoter is also associated with tumor prognosis. To evaluate this topic further, we conducted a systematic meta-analysis to explore the clinicopathological and prognostic significance of TIP30 for tumor patients.
  
  
  METHODS
  We searched PubMed and EMBASE for eligible studies. We manually searched for printed journals and relevant textbooks. Subgroup analyses were performed based on the region, manuscript quality, methods of vasculogenic mimicry identification, pathology, and number of patients.
  
  
  RESULTS
  Fourteen studies with 1705 patients were included in this meta-analysis. A significant association was observed between high expression of TIP30 in patients with cancer with a good overall survival (hazard ratio = 0.53, 95% confidence interval: 0.41-0.69), and good recurrence-free survival or disease free survival (hazard ratio = 0.49, 95% confidence interval: 0.37-0.66). Lack of expression of TIP30 had an association with lymph node metastasis (odds ratio = 3.90, 95% confidence interval: 2.21-6.89) and high tumor node metastasis clinical stage (odds ratio = 2.10, 95% confidence interval: 1.68-2.62). The methylation of the TIP30 promoter did not significantly influence the overall survival (hazard ratio = 0.99, 95% confidence interval: 0.88-1.13) or disease free survival (hazard ratio = 0.62, 95% confidence interval: 0.19-2.02).
  
  
  CONCLUSIONS
  TIP30 expression is associated with a good prognosis in patients with tumors. Clinical studies with large samples are needed worldwide and standardized protocols should be adopted in the future to achieve a better understanding of the relationship between tumor prognosis and TIP30.
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.|Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medicine Sciences, Haidian District, Beijing, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Xu
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.|Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
authors.forename: Honggang
authors.initials: H
authors.lastname: Zheng
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
authors.forename: Conghuang
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Hou
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.|Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.
authors.forename: Qiujun
authors.initials: Q
authors.lastname: Guo
authors.affiliation: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
authors.forename: Baojin
authors.initials: B
authors.lastname: Hua
mesh_terms: D000123:Acetyltransferases / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics*; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D011379:Prognosis; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D014157:Transcription Factors; D000123:Acetyltransferases; C111246:HTATIP2 protein, human